The recombinant proteins market size has grown rapidly in recent years. It will grow from $2.55 billion in 2025 to $2.89 billion in 2026 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to expansion of biologics-based drug development, rising prevalence of autoimmune and chronic diseases, growth in protein-based diagnostics, increasing use of recombinant insulin, advancements in expression system efficiency.
The recombinant proteins market size is expected to see rapid growth in the next few years. It will grow to $4.84 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing adoption of next-generation biologics, rising investments in biomanufacturing facilities, growing demand for personalized therapeutics, expansion of biosimilar development, increasing use of recombinant proteins in research. Major trends in the forecast period include increasing production of therapeutic antibodies, rising demand for recombinant enzymes, growing use of protein engineering techniques, expansion of biologics manufacturing capacity, enhanced focus on high-purity protein expression.
The increasing emphasis on personalized medicine is anticipated to drive the expansion of the recombinant protein market in the coming years. Personalized medicine is a healthcare approach that customizes treatments and therapies based on the individual characteristics, genetic makeup, and specific needs of each patient, aiming to deliver more precise and effective clinical outcomes. The rising adoption of personalized medicine is driven by advancements in genomic technologies and data analytics, which enable the development of therapies tailored to individual genetic profiles. Recombinant proteins support personalized medicine by facilitating the creation of targeted and customized therapies that align with a patient’s unique genetic and molecular characteristics, thereby enhancing treatment efficacy while minimizing adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, marking a notable increase from the six approvals recorded in 2022. Therefore, the growing focus on personalized medicine is contributing to the growth of the recombinant protein market going forward.
Major companies operating in the recombinant protein space are increasingly entering into partnerships to strengthen their competitive positioning. Such collaborations encourage innovation by leveraging complementary capabilities and expertise from multiple organizations. For example, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology company, partnered with Basic Pharma, a Netherlands-based pharmaceutical company. This collaboration includes a strategic partnership and co-marketing agreement focused on the development and production of non-GMP recombinant proteins, with an emphasis on creating a streamlined supply chain to accelerate time-to-market for new pharmaceutical products.
In May 2024, Sanofi, a France-based global healthcare company focused on the development of innovative pharmaceuticals, biologics, and therapies for rare diseases, acquired Inhibrx, Inc. for approximately $1.7 billion, along with a contingent value right. Through this acquisition, Sanofi obtains access to SAR447537, a differentiated human recombinant protein therapeutic designed to treat alpha-1 antitrypsin deficiency (AATD), thereby enhancing its recombinant protein portfolio, broadening its rare disease capabilities, and strengthening its pipeline depth and biologics innovation. Inhibrx, Inc. is a United States-based biopharmaceutical company specializing in the development of recombinant protein therapeutics and engineered biologics for rare diseases and oncology.
Major companies operating in the recombinant proteins market are Abcam plc, Abnova Corporation, Bio-Rad Laboratories Inc., Merck Co. & KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen- Cilag Pvt. Ltd., Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Crown Bioscience Inc., Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Eli Lilly and Company.
North America was the largest region in the recombinant protein market in 2025. The regions covered in the recombinant proteins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recombinant proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the recombinant proteins market by raising costs of imported cell culture media, purification resins, bioprocess equipment, and cold-chain logistics components. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported upstream and downstream processing inputs, while Asia-Pacific faces higher export production costs. These tariffs are increasing manufacturing expenses and pricing pressures for biologics. At the same time, they are encouraging domestic production of bioprocess consumables, local capacity expansion, and supply chain diversification across regions.
The recombinant proteins market research report is one of a series of new reports that provides recombinant proteins market statistics, including recombinant proteins industry global market size, regional shares, competitors with a recombinant proteins market share, detailed recombinant proteins market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant proteins industry. This recombinant proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Recombinant proteins are proteins that have been altered or edited using recombinant DNA technology. In this process, a plasmid is employed, containing the gene encoding the desired target protein, which is cloned downstream of a promoter region. These modified proteins find application in various fields, including pharmaceuticals, protein-based polymers for drug delivery, disease treatment through antibodies and enzymes, protein scaffolds for tissue engineering, and numerous other uses.
The primary types of recombinant protein products encompass antibodies, cytokines, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Antibodies, for example, are immune system components that circulate in the blood, identifying and neutralizing foreign objects such as bacteria and viruses. They are utilized across diverse applications, including drug and discovery development, therapeutics, research, and more. These recombinant proteins are predominantly utilized by pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and other relevant entities.
The recombinant protein market consists of sales of recombinant monoclonal antibodies, interferons, and interleukins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The recombinant proteins market size is expected to see rapid growth in the next few years. It will grow to $4.84 billion in 2030 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing adoption of next-generation biologics, rising investments in biomanufacturing facilities, growing demand for personalized therapeutics, expansion of biosimilar development, increasing use of recombinant proteins in research. Major trends in the forecast period include increasing production of therapeutic antibodies, rising demand for recombinant enzymes, growing use of protein engineering techniques, expansion of biologics manufacturing capacity, enhanced focus on high-purity protein expression.
The increasing emphasis on personalized medicine is anticipated to drive the expansion of the recombinant protein market in the coming years. Personalized medicine is a healthcare approach that customizes treatments and therapies based on the individual characteristics, genetic makeup, and specific needs of each patient, aiming to deliver more precise and effective clinical outcomes. The rising adoption of personalized medicine is driven by advancements in genomic technologies and data analytics, which enable the development of therapies tailored to individual genetic profiles. Recombinant proteins support personalized medicine by facilitating the creation of targeted and customized therapies that align with a patient’s unique genetic and molecular characteristics, thereby enhancing treatment efficacy while minimizing adverse effects. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for patients with rare diseases in 2023, marking a notable increase from the six approvals recorded in 2022. Therefore, the growing focus on personalized medicine is contributing to the growth of the recombinant protein market going forward.
Major companies operating in the recombinant protein space are increasingly entering into partnerships to strengthen their competitive positioning. Such collaborations encourage innovation by leveraging complementary capabilities and expertise from multiple organizations. For example, in October 2023, ARTES Biotechnology GmbH, a Germany-based biotechnology company, partnered with Basic Pharma, a Netherlands-based pharmaceutical company. This collaboration includes a strategic partnership and co-marketing agreement focused on the development and production of non-GMP recombinant proteins, with an emphasis on creating a streamlined supply chain to accelerate time-to-market for new pharmaceutical products.
In May 2024, Sanofi, a France-based global healthcare company focused on the development of innovative pharmaceuticals, biologics, and therapies for rare diseases, acquired Inhibrx, Inc. for approximately $1.7 billion, along with a contingent value right. Through this acquisition, Sanofi obtains access to SAR447537, a differentiated human recombinant protein therapeutic designed to treat alpha-1 antitrypsin deficiency (AATD), thereby enhancing its recombinant protein portfolio, broadening its rare disease capabilities, and strengthening its pipeline depth and biologics innovation. Inhibrx, Inc. is a United States-based biopharmaceutical company specializing in the development of recombinant protein therapeutics and engineered biologics for rare diseases and oncology.
Major companies operating in the recombinant proteins market are Abcam plc, Abnova Corporation, Bio-Rad Laboratories Inc., Merck Co. & KGaA, R&D Systems Inc., Proteintech Group Inc., RayBiotech Life Inc., GenScript Biotech Corporation, Elpiscience Biopharmaceuticals Co. Ltd., Elevian Inc., Gigagen Inc., Janssen- Cilag Pvt. Ltd., Sino Biological Inc., OriGene Technologies Inc., Feldan Therapeutics Inc., Bio-Techne Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Crown Bioscience Inc., Airway Therapeutics Inc., Amgen Inc., Aviva Systems Biology Corp., Eli Lilly and Company.
North America was the largest region in the recombinant protein market in 2025. The regions covered in the recombinant proteins market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the recombinant proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the recombinant proteins market by raising costs of imported cell culture media, purification resins, bioprocess equipment, and cold-chain logistics components. Pharmaceutical manufacturers in North America and Europe are most affected due to dependence on imported upstream and downstream processing inputs, while Asia-Pacific faces higher export production costs. These tariffs are increasing manufacturing expenses and pricing pressures for biologics. At the same time, they are encouraging domestic production of bioprocess consumables, local capacity expansion, and supply chain diversification across regions.
The recombinant proteins market research report is one of a series of new reports that provides recombinant proteins market statistics, including recombinant proteins industry global market size, regional shares, competitors with a recombinant proteins market share, detailed recombinant proteins market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant proteins industry. This recombinant proteins market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Recombinant proteins are proteins that have been altered or edited using recombinant DNA technology. In this process, a plasmid is employed, containing the gene encoding the desired target protein, which is cloned downstream of a promoter region. These modified proteins find application in various fields, including pharmaceuticals, protein-based polymers for drug delivery, disease treatment through antibodies and enzymes, protein scaffolds for tissue engineering, and numerous other uses.
The primary types of recombinant protein products encompass antibodies, cytokines, immune checkpoint proteins, virus antigens, enzymes, recombinant regulatory proteins, hormones, and others. Antibodies, for example, are immune system components that circulate in the blood, identifying and neutralizing foreign objects such as bacteria and viruses. They are utilized across diverse applications, including drug and discovery development, therapeutics, research, and more. These recombinant proteins are predominantly utilized by pharmaceutical and biotechnology companies, academic and research institutes, diagnostic laboratories, and other relevant entities.
The recombinant protein market consists of sales of recombinant monoclonal antibodies, interferons, and interleukins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Recombinant Proteins Market Characteristics
3. Recombinant Proteins Market Supply Chain Analysis
4. Global Recombinant Proteins Market Trends and Strategies
5. Recombinant Proteins Market Analysis of End Use Industries
7. Global Recombinant Proteins Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Recombinant Proteins Total Addressable Market (TAM) Analysis for the Market
9. Recombinant Proteins Market Segmentation
10. Recombinant Proteins Market Regional and Country Analysis
11. Asia-Pacific Recombinant Proteins Market
12. China Recombinant Proteins Market
13. India Recombinant Proteins Market
14. Japan Recombinant Proteins Market
15. Australia Recombinant Proteins Market
16. Indonesia Recombinant Proteins Market
17. South Korea Recombinant Proteins Market
18. Taiwan Recombinant Proteins Market
19. South East Asia Recombinant Proteins Market
20. Western Europe Recombinant Proteins Market
21. UK Recombinant Proteins Market
22. Germany Recombinant Proteins Market
23. France Recombinant Proteins Market
24. Italy Recombinant Proteins Market
25. Spain Recombinant Proteins Market
26. Eastern Europe Recombinant Proteins Market
27. Russia Recombinant Proteins Market
28. North America Recombinant Proteins Market
29. USA Recombinant Proteins Market
30. Canada Recombinant Proteins Market
31. South America Recombinant Proteins Market
32. Brazil Recombinant Proteins Market
33. Middle East Recombinant Proteins Market
34. Africa Recombinant Proteins Market
36. Recombinant Proteins Market Competitive Landscape and Company Profiles
37. Recombinant Proteins Market Other Major and Innovative Companies
40. Recombinant Proteins Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Recombinant Proteins Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses recombinant proteins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for recombinant proteins? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The recombinant proteins market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Antibodies; Cytokines; Virus Antigens; Enzymes; Recombinant Regulatory Proteins; Hormones; Other Products2) By Application: Drug And Discovery Development; Therapeutics; Research; Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Antibodies: Monoclonal Antibodies; Polyclonal Antibodies2) By Cytokines: Interleukins; Interferons; Tumor Necrosis Factors (TNFs)
3) By Virus Antigens: Viral Capsid Proteins; Envelope Proteins
4) By Enzymes: Restriction Enzymes; Polymerases; Ligases
5) By Recombinant Regulatory Proteins: Transcription Factors; Receptors
6) By Hormones: Insulin; Growth Hormones
7) By Other Products: Fusion Proteins; Peptide Therapeutics
Companies Mentioned: Abcam plc; Abnova Corporation; Bio-Rad Laboratories Inc.; Merck Co. & KGaA; R&D Systems Inc.; Proteintech Group Inc.; RayBiotech Life Inc.; GenScript Biotech Corporation; Elpiscience Biopharmaceuticals Co. Ltd.; Elevian Inc.; Gigagen Inc.; Janssen- Cilag Pvt. Ltd.; Sino Biological Inc.; OriGene Technologies Inc.; Feldan Therapeutics Inc.; Bio-Techne Corporation; Thermo Fisher Scientific Inc.; PerkinElmer Inc.; Crown Bioscience Inc.; Airway Therapeutics Inc.; Amgen Inc.; Aviva Systems Biology Corp.; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Recombinant Proteins market report include:- Abcam plc
- Abnova Corporation
- Bio-Rad Laboratories Inc.
- Merck Co. & KGaA
- R&D Systems Inc.
- Proteintech Group Inc.
- RayBiotech Life Inc.
- GenScript Biotech Corporation
- Elpiscience Biopharmaceuticals Co. Ltd.
- Elevian Inc.
- Gigagen Inc.
- Janssen- Cilag Pvt. Ltd.
- Sino Biological Inc.
- OriGene Technologies Inc.
- Feldan Therapeutics Inc.
- Bio-Techne Corporation
- Thermo Fisher Scientific Inc.
- PerkinElmer Inc.
- Crown Bioscience Inc.
- Airway Therapeutics Inc.
- Amgen Inc.
- Aviva Systems Biology Corp.
- Eli Lilly and Company
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.89 Billion |
| Forecasted Market Value ( USD | $ 4.84 Billion |
| Compound Annual Growth Rate | 13.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
